Roche reports very strong growth in the first nine months of 2018
Group sales increase 7% at constant exchange rates and in Swiss francs.
Pharmaceuticals Division sales up 7%, driven mainly by Ocrevus, Perjeta, Alecensa and Tecentriq.
Diagnostics Division sales grow 6%, primarily due to demand for immunodiagnostic solutions.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Switzerland Health